GAITHERSBURG, Md.--Gene Logic has announced a partnership with Hoechst Schering AgrEvo GmbH to develop novel crop protection and improvement products. A genomics company that has until now applied its products to human genome research, GeneLogic will construct an agricultural research database using its proprietary gene expression and bioinformatics technologies. Research and database fees paid by AgrEvo during the three-year term of the agreement could reach over $45 million, GeneLogic predicted. AgrEvo will also gain access to GeneLogic's proprietary Flow-Thru Chip technology for further analysis of genes identified in the research program.
GeneLogic also announced that it will acquire all outstanding Oncormed stock in a transaction valued at not more than $38 million. The combined company resulting from the merger will be a subsidiary of Gene Logic, based in Gene Logic's facility here. Gene Logic said Oncormed's proprietary technologies, resources, clinical experience, and portfolio of pharmacogenomics alliances will enable the combined companies to support aspects of drug discovery and development, including target identification and validation, the discovery of new drug leads, and clinical trials.